Dithiolethiones D3T and ACDT protect against iron overload-induced cytotoxicity and serve as ferroptosis inhibitors in U-87 MG cells

doi:10.21203/rs.3.rs-2476633/v1

Download PDF

Research Article

Dithiolethiones D3T and ACDT protect against iron overload-induced cytotoxicity and serve as ferroptosis inhibitors in U-87 MG cells

https://doi.org/10.21203/rs.3.rs-2476633/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 15 Apr, 2023

Read the published version in Neurochemical Research →

You are reading this latest preprint version

Iron overload-induced oxidative stress is implicated in various neurodegenerative disorders. Given the numerous adverse effects associated with current iron chelators, natural antioxidants are being explored as alternative therapeutic options. Dithiolethiones found in cruciferous vegetables have emerged as promising candidates against a wide range of toxicants owing to their lipophilic and cytoprotective properties. Here, we test the dithiolethiones D3T and ACDT against ferric ammonium citrate (FAC)-induced toxicity in U-87 MG astrocytoma cells. Exposure to 15 mM FAC for 24 hours resulted in 54% cell death. A 24-hour pretreatment with 50 µM D3T and ACDT prevented this cytotoxicity. Both dithiolethiones exhibited antioxidant effects by activating the Nrf2 transcription factor and upregulating levels of intracellular glutathione (GSH). This resulted in the successful inhibition of FAC-induced reactive oxygen species, lipid peroxidation, and cell death. Additionally, D3T and ACDT upregulated expression of the Nrf2-mediated iron storage protein ferritin which consequently reduced the total labile iron pool. A 24-hour pretreatment with D3T and ACDT also prevented cell death induced by the ferroptosis inducer erastin by upregulating the xCT transporter expression. The resulting increase in intracellular GSH and alleviation of lipid peroxidation was comparable to that caused by ferrostatin-1, a specific ferroptosis inhibitor. Collectively, our findings demonstrate that dithiolethiones may show promise as potential therapeutic options for the treatment of iron overload disorders.

Antioxidants

Dithiolethiones

Ferroptosis

Iron overload

Oxidative stress

Iron is a double-edged sword wherein both iron deficiency and iron overload conditions are deleterious to human health [1]. Although iron is essential for biological functions, the accumulation of this redox metal leads to the generation of reactive oxygen species (ROS) via the Fenton reaction [2]. ROS react with the polyunsaturated fatty acids in cell membranes leading to lipid peroxidation resulting in oxidative stress and eventual cell death. This underlying mechanism of iron-induced toxicity has also been implicated in neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, and Friedrich’s ataxia [3–5].

Astrocytes have gained a spotlight as models of iron-induced oxidative stress [6]. Anatomically, astrocytes are located immediately beyond the blood-brain barrier (BBB) serving as an additional protective layer to the neurons beyond. Physiologically, these cells serve as iron stores and gatekeepers for the transport of iron and other toxic substances into the brain [7]. They have been reported to scavenge free iron in the extracellular space of the brain and accumulate and store large amounts of iron, thereby protecting neuronal cells from iron-mediated oxidative stress [8]. Astrocytes, when cultured together with neurons, attenuate the cytotoxic effects of iron [9]. Therefore, any toxic damage to these protective astrocytes is also associated with neurodegeneration [10].

Dithiolethiones are organosulfur compounds that possess chemotherapeutic, anti-inflammatory, and antioxidative properties [11]. They are highly lipophilic and readily cross the BBB [12]. They are known to induce the phase-II antioxidant system via activation of the nuclear factor erythroid 2-related factor-2-Kelch-like ECH-associated protein-1 (Nrf2-Keap1) pathway. The disulfide group in dithiolethiones reacts with molecular oxygen to form hydrogen peroxide. This generates a small amount of oxidative stress disrupting the Nrf2-Keap1 complex and causing the free Nrf2 to translocate to the nucleus, bind to the antioxidant response element (ARE), and upregulate various antioxidant target genes [13].

3H-1,2-Dithiole-3-thione (D3T) and 5-amino-3-thioxo-3H-(1,2) dithiole-4-carboxylic acid ethyl ester (ACDT) are dithiolethiones that have previously shown neuroprotective effects both in vitro and in vivo. D3T is the most potent unsubstituted parent compound in this series and has displayed neuroprotective activity in a murine AD model [14]. Additionally, D3T has displayed protection in models of neuroinflammation [15], stroke [16], and amyloid beta-induced toxicity [17]. ACDT, a disubstituted dithiolethione with pharmacokinetically favorable functional groups (Munday 2010) has exhibited protection against neuroinflammation [18], a 6-hydroxydopamine model of PD [19], and manganese-induced neurotoxicity [20]. Overlap in the toxicity profiles of manganese and iron as well as the strong association of iron with neurodegenerative diseases including PD and AD led us to explore the protective role of these dithiolethiones against iron-induced toxicity in human astrocytoma (U-87 MG) cells. We hypothesize that activation of the Nrf2 pathway by dithiolethiones will protect U-87 MG cells against ferric ammonium citrate (FAC)-induced oxidative stress and cell death.

Reagents and supplies

U-87 MG human glioblastoma cells (ATCC© HTB-14) and Eagle’s Minimum Essential Medium (EMEM, 30-2003) were procured from American Type Culture Collection (ATCC, Manassas, VA). Bicinchoninic acid assay kit (BCA, 23225) and calcein-AM cell-permeant dye (C1430), and fetal bovine serum (FBS, 1600044) were purchased from ThermoFisher Scientific (Waltham, MA). Ferric ammonium citrate (FAC, F5879), and 2′,7′-dichlorofluorescein diacetate dye (DCFDA, D6883) were ordered from Sigma Aldrich (St. Louis, MO). CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS, G3580) and the luminescence-based GSH-Glo glutathione assay kit (V6911) were purchased from Promega (Madison, WI). Erastin (17754), ferrostatin-1 (17729), and TBARS Assay Kit® (10009055) were procured from Cayman Chemical (Ann Arbor, MI).

Cell culture

Human glioblastoma (U-87 MG) cells were cultured in EMEM supplemented with 10% FBS and 1% penicillin/streptomycin in a humidified atmosphere with 5% CO₂ at 37℃.

Cell viability assay

The FAC salt was used to induce iron toxicity owing to its readily water-soluble property and widespread use in past studies [21–23]. For a baseline toxicity evaluation, U-87 MG cells were treated with FAC (0–20 mM) for 24 hours. To examine the protective ability of dithiolethiones against iron toxicity, the cells were pretreated with 50 µM D3T or ACDT for 24 hours before exposure to 15 mM of FAC for an additional 24 hours. To evaluate if D3T and ACDT act as ferroptosis inhibitors, cells were pretreated with dithiolethiones or with ferrostatin-1 (positive control), followed by subsequent exposure to the ferroptosis-inducer erastin. As a general setup, pretreated compounds were always aspirated before the addition of the toxicant. The MTS assay was used to determine cell viability as previously described [24] and absorbance was measured at a wavelength of 490 nm using the Synergy HT multimode microplate reader (Biotek Instruments, Winooski, VT).

Microscopy

Using an exposure setup similar to the cell viability assay, U-87 MG cells at a density of 1x10⁶ per group were treated with D3T, ACDT, and FAC alone and in combination. Cell morphology changes were captured at a phase-contrast mode using the Keyence All-in-One Fluorescence Microscope (BZ-X800, Woburn, MA).

Measurement of intracellular ROS

ROS levels were determined using the DCFDA dye following the manufacturer’s protocol. Briefly, 5x10⁴ cells/well were seeded in 96-well black microplates (3916, Corning®) and were incubated with a 10 µM DCFDA fluorescent probe in phenol red-free media for 45 minutes. After removal of the dye, cells were treated with compounds and fluorescence signals directly proportional to the levels of intracellular ROS levels were measured at excitation/emission wavelengths of 495/529 nm.

Measurement of intracellular glutathione (GSH) levels

U-87 MG cells were pretreated with 50 µM D3T or ACDT for 24 hours followed by exposure to 15 mM FAC for an additional 24 hours. For ferroptosis experiments, 20 µM erastin was used as a ferroptosis inducer. The GSH-Glo glutathione assay kit was used to determine GSH concentration according to the manufacturer’s instructions.

Lipid peroxidation assay

Treated U-87 MG cells were lysed, and the thiobarbituric acid reactive substances (TBARS) assay was performed according to the manufacturer’s instructions. The absorbance values were measured at 540 nm and malondialdehyde (MDA) levels were normalized to a standard curve.

Western blot analysis

A standard western blotting protocol was followed using 40 µg of total protein. Recombinant anti-ferritin monoclonal antibody (ab75973, 1:1000, Abcam®), anti-Nrf2 polyclonal antibody (ab31163, 1:500), anti-ferroportin monoclonal antibody (ab239511, 1:1000, Abcam®), anti-xCT monoclonal antibody (ab175186, 1:1000, Abcam®), anti-GCLC monoclonal antibody (ab181839, 1:10000, Abcam®), HRP goat anti-rabbit secondary antibody H&L (ab97051, 1:10000, Abcam®), and the anti-beta actin antibody (HRP) (ab49900, 1:20000, Abcam®) were used. The bands were visualized using a C-Digit Scanner (Li-COR Biosciences, Lincoln, NE) and the Image Studio Lite® (Li-COR Biosciences, Lincoln, NE) program was used for densitometric analysis. The protein levels were calculated relative to the vehicle control.

Calcein-AM assay

Cells at a density of 5×10⁴ cells/well in a clear-bottom black 96-well plate were pretreated with D3T or ACDT before exposure to FAC for 2 hours. After aspiration of media, the cells were incubated with 3 µM calcein-AM fluorescent dye for 45 minutes. The dye was aspirated, and the cells were incubated for another 15 mins with the serum-free media. The fluorescence was measured at excitation/emission wavelengths of 485/528 nm using the Synergy HT Multi-Mode Microplate Reader.

Statistical analysis

Data are reported as mean ± SD. Comparisons between multiple groups were performed using a one-way analysis of variance (ANOVA) followed by an appropriate post hoc test. Results with a p-value ≤ 0.05 were considered statistically significant. Each experiment was performed at least three times (n = 3). GraphPad Prism version 8.0 for Windows (La Jolla, CA) was utilized for statistical analyses and graphical representations of the data.

Impact of dithiolethiones on FAC-induced cell death

A 24-hour exposure of U-87 MG cells to FAC (0–20 mM) resulted in concentration-dependent cytotoxicity (Fig. 1a). As the cell viability decreased to 54% (F_9,20 = 31.62; p < 0.0001) with 15 mM FAC, this concentration was selected for subsequent experiments. Pretreatment with 50 µM of D3T or ACDT significantly increased the cell viability to 94% and 90%, respectively in comparison to the FAC alone-treated group (Fig. 1b) (F_7,16 = 31.05; p < 0.0001). The dithiolethiones alone had no impact on cell viability. Cells treated with 15 mM FAC alone were visually sparse in number and appeared rounded in comparison to those in the control group, while cells pretreated with the dithiolethiones appeared morphologically healthier (Fig. 1c).

Impact of dithiolethiones on FAC-induced oxidative stress

To determine the Nrf2-dependent antioxidant effects of dithiolethiones, we evaluated the expression levels of the Nrf2 transcription factor and glutamate-cysteine ligase catalytic (GCLC) protein. A 4-hour exposure to D3T or ACDT alone significantly upregulated the expression of Nrf2 levels in U-87 MG cells to 1.6-fold each (F_2,6 = 19.24, p < 0.01) (Fig. 2a). Likewise, 24-hour treatment with D3T and ACDT alone upregulated GCLC protein levels to 1.7- and 1.8-fold, respectively, and pretreatment with D3T and ACDT prior to FAC exposure increased GCLC expression from 0.8-fold to 1.5- and 1.4-fold, respectively (Fig. 2b). These strong trends however were not statistically significant. Compared to control cells, 15 mM FAC exposure significantly decreased the intracellular GSH level (0.7 µM), and this was upregulated by pretreatment with D3T and ACDT to 1.1 and 1.3 µM, respectively (F_7,16 = 72.52; p < 0.0001, Fig. 2c). The increase in GSH levels by D3T and ACDT alone were not statistically significant. FAC induced a significant increase in intracellular ROS levels peaking to 2.0-fold at 4 hours (F_7,16 = 102.33; p < 0.0001, Fig. 2d), and this was successfully countered by dithiolethione pretreatment (F_7,16 = 48.32; p < 0.0001) (Fig. 2e). Similarly, an FAC-induced increase in MDA levels (38.3 to 53.5 µM) was successfully countered by pretreatment with D3T (40.3 µM) and ACDT (40.7 µM) (F_5,12 = 16.06; p < 0.0001, Fig. 2f). Data therefore indicate that pretreatment with these dithiolethiones upregulates the cellular antioxidant defense via activation of the Nrf2-ARE pathway which helps rescue U-87 MG cells from FAC-induced oxidative stress.

Impact of dithiolethiones on intracellular iron levels

While exposure to FAC alone significantly upregulated (2.4-fold) the expression of the iron storage protein ferritin, pretreatment with D3T and ACDT increased this level even further (4.1- and 3.1-fold), respectively (F_7,16 = 20.24; p < 0.0001, Fig. 3a). There was also a visible trend with D3T alone (1.3-fold) and as a pretreatment to FAC (0.6 to 0.9-fold) upregulating the expression of the iron exporter ferroportin (FPN) (F_5,12 = 3.22; ns, Fig. 3b). A significant decrease in the relative calcein-AM fluorescence on exposure to FAC alone for 2 hours (0.5-fold vs control) indicated an increased intracellular labile iron pool, which was successfully countered by a 24-hour pretreatment with D3T and ACDT to 0.7-fold each. Notably, treatment with D3T alone also significantly reduced free iron levels (F_5,12 = 131.80; p < 0.0001, Fig. 3c).

Impact of dithiolethiones on erastin-induced ferroptosis

To test if dithiolethiones serve as inhibitors of ferroptosis, we used erastin and ferrostatin-1 as standard ferroptosis-inducer and inhibitor controls respectively. An erastin-induced decrease in xCT protein expression (0.4-fold) was prevented by pretreatment with both dithiolethiones and ferrostatin-1 (F_4,10 = 13.40, p = 0.0005, Fig. 4a). Consequently, the erastin-induced depletion of the intracellular GSH levels (0.2-fold, F_4,10 = 77.30, p < 0.0001) was also successfully prevented by pretreatment with D3T, ACDT, and ferrostatin-1 to 0.5-fold, 0.4-fold, and 0.5-fold, respectively (Fig .4b). D3T, ACDT, and ferrostatin-1 also reduced the erastin-induced increase in MDA levels from 17.7 µM down to 8.4 µM, 7.6 µM, and 6.5 µM, respectively (F_4,10 = 11.74, p < 0.0001, Fig. 4c), and the erastin-induced reduction in cell viability from 75–102%, 91%, and 90%, respectively (F_4,10 = 22.9, p < 0.0001, Fig. 4d). These results show that these dithiolethiones act as inhibitors of erastin-induced ferroptosis in U-87 MG cells comparable to ferrostatin-1.

Iron overload is a serious problem that is often overlooked because of the non-specificity and gradual development of symptoms. Examples of iron-overload induced toxicity are widespread. Hemochromatosis, a common genetic disorder, results in iron accumulation in the liver, heart, and skin [25]. Accidental iron poisoning and death in children are also common because of the candy-like appearance of iron preparations used in treating anemia [26]. Iron overload and accumulation are linked to various diseases such as PD, AD, and neurodegeneration associated with brain iron accumulation [27]. The current therapeutic approach in treating iron toxicity is the use of iron chelators such as deferoxamine, deferiprone, and deferasirox [28]. Given the wide range of adverse effects such as gastrointestinal disorders, nephrotoxicity, and agranulocytosis associated with these iron chelators [29], exogenous antioxidants such as N-acetylcysteine, flavonoids, carotenoids, and diterpenes have also been explored as potential therapeutic options [30, 31]. Based on the promising antioxidant activity and favorable pharmacokinetic and safety profiles of dithiolethiones [32], we investigated their effects against iron-induced cytotoxicity in U-87 MG astrocytoma cells. While D3T and ACDT have previously been shown to be cytoprotective against various toxicants, this is the first study to test their effects against iron-induced toxicity. We chose 50 µM as the test concentration for both dithiolethiones based on data from past studies [19, 33]. The color of FAC did not interfere with any of the assays used in our study, as readings from wells containing FAC without cells did not differ from wells containing media alone. The relatively high (15 mM) concentration of FAC required in our study is likely due to the cell line itself, as astrocytes can store large amounts of iron and are more resistant to toxicity compared to neurons [34]. The role of astrocytes as gatekeepers to neurons has been described previously, suggesting that protecting astrocytes could indirectly protect neurons from toxic insult [35, 36].

Oxidative stress is believed to be the principal mechanism of iron-induced toxicity. Iron is a transition metal that catalyzes the formation of ROS, depletion of intracellular antioxidants, and overall cellular oxidative damage [37]. By causing the nuclear translocation of Nrf2, dithiolethiones activate ARE and initiate the transcription of various antioxidant genes [11] such as catalytic subunit of glutamate cysteine ligase GCLC. The enzyme GCLC catalyzes the rate-limiting step in GSH synthesis, a natural cellular antioxidant. The increase in Nrf2 levels typically occurs early (between 2–6 hours) and is a transient event [19, 38]. Therefore, while we measured the changes in Nrf2 levels with dithiolethiones alone, the impact of these compounds as pretreatment prior to FAC exposure could not be assessed due to the extended timeline. Similar to previous results, we identified a dithiolethione-induced increase in Nrf2 levels to explain the trends in increased GCLC and GSH levels observed [19, 38, 39]. This impact was much more prominent in pretreated cells, and further exhibited by the significant decrease in ROS and lipid peroxidation levels in FAC-exposed astrocytic cells pretreated with dithiolethiones. It is noteworthy that basal GSH levels in neurons are lower than those in astrocytes and reportedly increase when neurons are co-incubated with astrocytes [40]. A dithiolethione-mediated increase in GSH levels in astrocytic cells could therefore be hypothesized to benefit adjacent neurons as well.

The labile iron pool is strictly regulated by various mechanisms including the Nrf2-mediated transcriptional upregulation of ferritin and ferroportin (FPN1) expression [41]. Both these proteins reduce cellular iron levels. Ferritin is an intracellular iron storage protein that stores excess iron in a redox inactive form [42], while FPN1 is the iron exporter that exports iron from the cell into the plasma [43]. Incubation with ferric iron has previously been reported to increase ferritin expression in Caco-2 cells [44] and astrocytes [23] as a potential cellular defense mechanism against iron overload. Pretreatment with D3T and ACDT further increased ferritin expression likely based on activation of the Nrf2-ferritin-ARE pathway. In line with the results from Tangudu and group [45], we observed trends for of an FAC-induced decrease and D3T-mediated increase in FPN1 levels, but these were not statistically significant and may only have partly contributed to the overall decrease in intracellular free iron levels observed in this study. There is also a possibility that the time point chosen for FPN1 protein level analysis may have impacted our results. Nrf2 levels were found to increase as early as with a 4 hour exposure to these compounds, suggesting that an impact on FPN1 levels may have diminished by the time of testing. In line with other studies [46], we have reported measurement of labile iron with a shorter (2 hour) exposure to FAC to account for the stability of the calcein-AM dye. Notably, D3T alone showed a strong trend towards increased ferritin and ferroportin levels eventually causing significant reduction in labile iron level. Even though a mild degree of anemia has previously been reported with high doses of D3T in animal studies [47], this dithiolethione is still considered relatively safe compared to the currently available iron chelators.

Recent research has expanded to other forms of iron-induced cell death such as ferroptosis. First coined in 2012, ferroptosis is an iron-dependent, non-apoptotic cell death characterized by increased lipid peroxidation and associated with reduced intracellular antioxidant capacity [48]. It is morphologically, biochemically, and genetically distinct from all other forms of cell death. Inhibition of intracellular antioxidants such as GSH and glutathione peroxidase (GPX4) by the known ferroptosis inducers erastin and RAS-selective lethal-3 (RSL3) leads to oxidative stress and lipid peroxidation which then drive ferroptosis [49]. Astrocytes have been found to be susceptible to ferroptosis induced by erastin and RSL3 [50]. Ferroptosis is inhibited by iron chelators and lipophilic antioxidants [51]. The Nrf2 transcription factor has been reported to upregulate the expression of various ferroptosis-related proteins like xCT and GPX4 thereby inhibiting ferroptosis [52]. A previous study has proposed that D3T could potentially offer protection against ferroptosis since it has the ability to activate Nrf2, but this has not been tested yet [53]. We investigated the effects of D3T and ACDT against the canonical ferroptosis inducer erastin using ferrostatin-1 as a standard comparator. Ferrostatin-1 is a lipophilic antioxidant that specifically inhibits ferroptosis by preventing lipid peroxidation without affecting any other forms of cell death [54]. Erastin causes ferroptosis by inhibiting the transmembrane cystine/glutamate antiporter (xCT). This transporter normally allows the uptake of cystine into the cells which is then reduced to cysteine, a molecule indispensable for GSH synthesis. Therefore, inhibition of xCT leads to a decrease in cysteine levels and consequent intracellular GSH depletion, increased lipid peroxidation, and resulting ferroptosis [55]. Our results align with previous reports of erastin-induced downregulation of xCT expression and increase in lipid peroxidation in primary cortical neurons [56], and GSH depletion in human cervical adenocarcinoma cells [55] and HT-1080 human fibrosarcoma cells [57]. Moreover, an increase in the xCT expression by D3T and ACDT against erastin is one of our key findings which can at least partly be explained by the activation of the Nrf2-ARE pathway that controls the expression of this antiporter [58]. A corresponding increase in GSH levels was also observed with dithiolethione pretreatment, along with a reduction in lipid peroxidation and cell death. These effects were similar to those observed with ferrostatin-1 which is also reported to induce the Nrf2 transcription factor [59]. Even though the concentration of dithiolethiones (50 µM) used here is higher than that of ferrostatin-1 (10 µM), dithiolethiones offer the advantage of being of natural origin. Ferrostatin-1 is not available for therapeutic use. These results imply that dithiolethiones can successfully protect cells against the ferroptotic form of cell death.

A potential limitation of this study includes the lack of corresponding data on neuronal cells. As a future study, we suggest using a co-culture technique to test the cytoprotective effects of dithiolethiones on astrocytes and adjacent neurons. Further mechanistic studies to test the role of dithiolethiones against other ferroptosis inducers and in other cell lines are also warranted given the complex and evolving nature of this newly discovered form of cell death.

In conclusion, this study is the first to report that dithiolethiones D3T and ACDT exert significant cytoprotection against iron overload-induced cytotoxicity in U-87 MG cells. Using a Nrf2-dependent pathway, dithiolethiones prevent cell death by upregulating ferritin and GSH expression and reducing ROS production and lipid peroxidation. These dithiolethiones also successfully inhibit erastin-induced ferroptosis by increasing xCT expression and resulting GSH levels, alleviating lipid peroxidation, thereby protecting against ferroptotic cell death comparable to ferrostatin-1 (Fig. 5). Hence for the first time, we introduce dithiolethiones D3T and ACDT as ferroptosis inhibitors and provide compelling evidence to support their further investigation as strong candidates for the treatment of iron overload conditions.

Acknowledgments

This study was funded by Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Boston, MA. The authors would like to acknowledge Dr. Dennis Brown from Manchester University, College of Pharmacy, Natural & Health Sciences, Fort Wayne, IN for his scientific input.

Competing interests

The authors have no relevant financial or non-financial interests to declare.

Author contributions

Neha Kulkarni: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curation, Writing an initial draft, Visualization. Rajitha Gadde: Validation, Formal analysis, Investigation, Data curation, Writing an initial draft. Swati Betharia: Conceptualization, Methodology, Data curation, Writing- editing, critical review, and revision of the manuscript, Supervision, Project administration, Funding acquisition.

Youssef LA, Spitalnik SL. Iron: a double-edged sword. Transfusion. 2017;57(10):2293-7. doi: 10.1111/trf.14296.
Jaishankar M, Tseten T, Anbalagan N, Mathew BB, Beeregowda KN. Toxicity, mechanism and health effects of some heavy metals. Interdiscip Toxicol. 2014;7(2):60-72. doi: 10.2478/intox-2014-0009.
Li K, Reichmann H. Role of iron in neurodegenerative diseases. J Neural Transm (Vienna). 2016;123(4):389-99. doi: 10.1007/s00702-016-1508-7.
Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem. 2011;118(6):939-57. doi: 10.1111/j.1471-4159.2010.07132.x.
Gordon N. Friedreich's ataxia and iron metabolism. Brain Dev. 2000;22(8):465-8. doi: 10.1016/s0387-7604(00)00175-3.
Allaman I, Belanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 2011;34(2):76-87. doi: 10.1016/j.tins.2010.12.001.
Phatnani H, Maniatis T. Astrocytes in neurodegenerative disease. Cold Spring Harb Perspect Biol. 2015;7(6). doi: 10.1101/cshperspect.a020628.
Reinert A, Morawski M, Seeger J, Arendt T, Reinert T. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci. 2019;20(1):25. doi: 10.1186/s12868-019-0507-7.
Bishop GM, Dang TN, Dringen R, Robinson SR. Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia. Neurotox Res. 2011;19(3):443-51. doi: 10.1007/s12640-010-9195-x.
Gaasch JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ. Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem Res. 2007;32(7):1196-208. doi: 10.1007/s11064-007-9290-4.
Ansari MI, Khan MM, Saquib M, Khatoon S, Hussain MK. Dithiolethiones: a privileged pharmacophore for anticancer therapy and chemoprevention. Future Med Chem. 2018;10(10):1241-60. doi: 10.4155/fmc-2017-0281.
Munday R, Zhang Y, Paonessa JD, Munday CM, Wilkins AL, Babu J. Synthesis, biological evaluation, and structure-activity relationships of dithiolethiones as inducers of cytoprotective phase 2 enzymes. J Med Chem. 2010;53(12):4761-7. doi: 10.1021/jm100425v.
Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res. 2001;480-481:305-15. doi: 10.1016/s0027-5107(01)00190-7.
Cui Y, Ma S, Zhang C, Li D, Yang B, Lv P, et al. Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease. Behav Brain Res. 2018;336:219-26. doi: 10.1016/j.bbr.2017.09.011.
Kuo PC, Brown DA, Scofield BA, Yu IC, Chang FL, Wang PY, et al. 3H-1,2-dithiole-3-thione as a novel therapeutic agent for the treatment of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2016;57:173-86. doi: 10.1016/j.bbi.2016.03.015.
Kuo PC, Yu IC, Scofield BA, Brown DA, Curfman ET, Paraiso HC, et al. 3H-1,2-Dithiole-3-thione as a novel therapeutic agent for the treatment of ischemic stroke through Nrf2 defense pathway. Brain Behav Immun. 2017;62:180-92. doi: 10.1016/j.bbi.2017.01.018.
Zhang C, Xie L, Guan F, Cui Y. 3H-1,2-dithiole-3-thione protects PC12 cells against amyloid beta 1-42 (Abeta1-42) induced apoptosis via activation of the ERK1/2 pathway. Life Sci. 2018;213:74-81. doi: 10.1016/j.lfs.2018.10.025.
Kuo PC, Brown DA, Scofield BA, Paraiso HC, Wang PY, Yu IC, et al. Dithiolethione ACDT suppresses neuroinflammation and ameliorates disease severity in experimental autoimmune encephalomyelitis. Brain Behav Immun. 2018;70:76-87. doi: 10.1016/j.bbi.2018.03.010.
Betharia S, Rondomicronn-Ortiz AN, Brown DA. Disubstituted Dithiolethione ACDT Exerts Neuroprotective Effects Against 6-Hydroxydopamine-Induced Oxidative Stress in SH-SY5Y Cells. Neurochem Res. 2019;44(8):1878-92. doi: 10.1007/s11064-019-02823-3.
Kulkarni N, Gadde R, Gugnani KS, Vu N, Yoo C, Zaveri R, et al. Neuroprotective effects of disubstituted dithiolethione ACDT against manganese-induced toxicity in SH-SY5Y cells. Neurochem Int. 2021;147:105052. doi: 10.1016/j.neuint.2021.105052.
Eid R, Arab NT, Greenwood MT. Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms. Biochim Biophys Acta Mol Cell Res. 2017;1864(2):399-430. doi: 10.1016/j.bbamcr.2016.12.002.
Karim A, Bajbouj K, Shafarin J, Qaisar R, Hall AC, Hamad M. Iron Overload Induces Oxidative Stress, Cell Cycle Arrest and Apoptosis in Chondrocytes. Front Cell Dev Biol. 2022;10:821014. doi: 10.3389/fcell.2022.821014.
Hoepken HH, Korten T, Robinson SR, Dringen R. Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J Neurochem. 2004;88(5):1194-202. doi: 10.1046/j.1471-4159.2003.02236.x.
Geng N, Shi BJ, Li SL, Zhong ZY, Li YC, Xua WL, et al. Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells. Eur Rev Med Pharmacol Sci. 2018;22(12):3826-36. doi: 10.26355/eurrev_201806_15267.
Wood MJ, Skoien R, Powell LW. The global burden of iron overload. Hepatol Int. 2009;3(3):434-44. doi: 10.1007/s12072-009-9144-z.
Yuen HW, Becker W. Iron Toxicity. StatPearls. Treasure Island (FL)2022.
Schneider SA, Bhatia KP. Excess iron harms the brain: the syndromes of neurodegeneration with brain iron accumulation (NBIA). J Neural Transm (Vienna). 2013;120(4):695-703. doi: 10.1007/s00702-012-0922-8.
Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A Review on Iron Chelators in Treatment of Iron Overload Syndromes. Int J Hematol Oncol Stem Cell Res. 2016;10(4):239-47.
Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012;10(4):411-22. doi: 10.2450/2012.0008-12.
Shen JC, Zhang YC, Zhao MF. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow. Braz J Med Biol Res. 2017;50(12):e6087. doi: 10.1590/1414-431X20176087.
Sarkar R, Hazra B, Mandal N. Hepatoprotective Potential of Caesalpinia crista against Iron-Overload-Induced Liver Toxicity in Mice. Evid Based Complement Alternat Med. 2012;2012:896341. doi: 10.1155/2012/896341.
Jia Z, Zhu H, Li Y, Misra HP. Cruciferous nutraceutical 3H-1,2-dithiole-3-thione protects human primary astrocytes against neurocytotoxicity elicited by MPTP, MPP(+), 6-OHDA, HNE and acrolein. Neurochem Res. 2009;34(11):1924-34. doi: 10.1007/s11064-009-9978-8.
Dong J, Yan D, Chen SY. Stabilization of Nrf2 protein by D3T provides protection against ethanol-induced apoptosis in PC12 cells. PLoS One. 2011;6(2):e16845. doi: 10.1371/journal.pone.0016845.
Codazzi F, Pelizzoni I, Zacchetti D, Grohovaz F. Iron entry in neurons and astrocytes: a link with synaptic activity. Front Mol Neurosci. 2015;8:18. doi: 10.3389/fnmol.2015.00018.
Linnerbauer M, Rothhammer V. Protective Functions of Reactive Astrocytes Following Central Nervous System Insult. Front Immunol. 2020;11:573256. doi: 10.3389/fimmu.2020.573256.
Gleixner AM, Posimo JM, Pant DB, Henderson MP, Leak RK. Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury. Mol Neurobiol. 2016;53(7):4939-60. doi: 10.1007/s12035-015-9427-4.
Gammella E, Recalcati S, Cairo G. Dual Role of ROS as Signal and Stress Agents: Iron Tips the Balance in favor of Toxic Effects. Oxid Med Cell Longev. 2016;2016:8629024. doi: 10.1155/2016/8629024.
Li KR, Yang SQ, Gong YQ, Yang H, Li XM, Zhao YX, et al. 3H-1,2-dithiole-3-thione protects retinal pigment epithelium cells against Ultra-violet radiation via activation of Akt-mTORC1-dependent Nrf2-HO-1 signaling. Sci Rep. 2016;6:25525. doi: 10.1038/srep25525.
Dong J, Sulik KK, Chen SY. Nrf2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in vivo: implications for the prevention of fetal alcohol spectrum disorders. Antioxid Redox Signal. 2008;10(12):2023-33. doi: 10.1089/ars.2007.2019.
Aoyama K. Glutathione in the Brain. Int J Mol Sci. 2021;22(9). doi: 10.3390/ijms22095010.
Kerins MJ, Ooi A. The Roles of NRF2 in Modulating Cellular Iron Homeostasis. Antioxid Redox Signal. 2018;29(17):1756-73. doi: 10.1089/ars.2017.7176.
Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, et al. Physiology of iron metabolism. Transfus Med Hemother. 2014;41(3):213-21. doi: 10.1159/000362888.
Drakesmith H, Nemeth E, Ganz T. Ironing out Ferroportin. Cell Metab. 2015;22(5):777-87. doi: 10.1016/j.cmet.2015.09.006.
Lin JF, Wu CC, Liao YJ, Jakfar S, Tang ZB, Chen JK, et al. In Vitro and In Vivo Evaluations of Mesoporous Iron Particles for Iron Bioavailability. Int J Mol Sci. 2019;20(21). doi: 10.3390/ijms20215291.
Tangudu NK, Alan B, Vinchi F, Worle K, Lai D, Vettorazzi S, et al. Scavenging Reactive Oxygen Species Production Normalizes Ferroportin Expression and Ameliorates Cellular and Systemic Iron Disbalances in Hemolytic Mouse Model. Antioxid Redox Signal. 2018;29(5):484-99. doi: 10.1089/ars.2017.7089.
Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, et al. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. J Leukoc Biol. 2019;105(5):1015-26. doi: 10.1002/JLB.3A0318-108R.
Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther. 2008;7(11):3470-9. doi: 10.1158/1535-7163.MCT-08-0625.
Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med. 2019;133:130-43. doi: 10.1016/j.freeradbiomed.2018.09.043.
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. doi: 10.1186/s13045-019-0720-y.
Jiao L, Li X, Luo Y, Wei J, Ding X, Xiong H, et al. Iron metabolism mediates microglia susceptibility in ferroptosis. Front Cell Neurosci. 2022;16:995084. doi: 10.3389/fncel.2022.995084.
Han C, Liu Y, Dai R, Ismail N, Su W, Li B. Ferroptosis and Its Potential Role in Human Diseases. Front Pharmacol. 2020;11:239. doi: 10.3389/fphar.2020.00239.
Song X, Long D. Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases. Front Neurosci. 2020;14:267. doi: 10.3389/fnins.2020.00267.
Zhu H, Santo A, Jia Z, Robert Li Y. GPx4 in Bacterial Infection and Polymicrobial Sepsis: Involvement of Ferroptosis and Pyroptosis. React Oxyg Species (Apex). 2019;7(21):154-60. doi: 10.20455/ros.2019.835.
Miotto G, Rossetto M, Di Paolo ML, Orian L, Venerando R, Roveri A, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328. doi: 10.1016/j.redox.2019.101328.
Shibata Y, Yasui H, Higashikawa K, Miyamoto N, Kuge Y. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. PLoS One. 2019;14(12):e0225931. doi: 10.1371/journal.pone.0225931.
Zhang Y, Fan BY, Pang YL, Shen WY, Wang X, Zhao CX, et al. Neuroprotective effect of deferoxamine on erastininduced ferroptosis in primary cortical neurons. Neural Regen Res. 2020;15(8):1539-45. doi: 10.4103/1673-5374.274344.
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1-2):317-31. doi: 10.1016/j.cell.2013.12.010.
Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buchfelder M, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6(8):e371. doi: 10.1038/oncsis.2017.65.
Chu J, Liu CX, Song R, Li QL. Ferrostatin-1 protects HT-22 cells from oxidative toxicity. Neural Regen Res. 2020;15(3):528-36. doi: 10.4103/1673-5374.266060.

No competing interests reported.

Download PDF

Journal Publication

published 15 Apr, 2023

Read the published version in Neurochemical Research →

Editorial decision: Major revision
27 Feb, 2023
Reviews received at journal
23 Feb, 2023
Reviewers agreed at journal
05 Feb, 2023
Reviews received at journal
04 Feb, 2023
Reviewers agreed at journal
30 Jan, 2023
Reviewers invited by journal
20 Jan, 2023
Editor assigned by journal
17 Jan, 2023
Submission checks completed at journal
16 Jan, 2023
First submitted to journal
13 Jan, 2023

You are reading this latest preprint version

Dithiolethiones D3T and ACDT protect against iron overload-induced cytotoxicity and serve as ferroptosis inhibitors in U-87 MG cells

Status:

Journal Publication

Version 1

Abstract

Figures

1. Introduction

2. Materials And Methods

3. Results

4. Discussion

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1